Shares of Biogen Idec Inc. (NASDAQ: BIIB) gained in premarket hours on Thursday after the FDA said late on Wednesday that it has approved the biotechnology Company’s new multiple sclerosis drug, Tecfidera.
Continue reading FDA Approves Biogen Idec’s Potential Blockbuster Treatment for MS (BIIB)